컴퓨터 병리학 시장, 규모, 점유율 및 동향 분석 : 제품 및 서비스별, 도입 모드별, 용도별, 최종사용자별, 지역별 -기회 분석 및 업계 예측

The global Computational Pathology market is estimated to be valued at USD 0.80 billion in 2026 and is projected to reach USD 2.06 billion by 2036, expanding at a CAGR of 9.9% during the forecast period. The report provides a comprehensive evaluation of the rapidly evolving digital and AI-driven diagnostics landscape transforming traditional pathology workflows, examining market trends, technological advancements, competitive developments, and future growth opportunities across the value chain.

Computational pathology is fundamentally transforming diagnostic medicine by shifting the field from manual microscopy toward advanced, AI-driven digital workflows built on whole-slide imaging and sophisticated image analysis algorithms. As the global healthcare sector faces an escalating cancer burden alongside a critical shortage of specialized pathologists, computational tools have become essential for enhancing diagnostic accuracy, throughput, and reproducibility. Hospitals, pharmaceutical companies, and research institutions across the globe are increasingly adopting these platforms to identify subtle morphological features and manage rising testing volumes.

This report delivers an in-depth assessment of the market by analyzing technological innovations, adoption trends, regulatory considerations, and competitive developments influencing industry growth. It evaluates how computational pathology is reshaping diagnostic workflows, from AI-based tissue segmentation and biomarker quantification to integration with genomic and proteomic data for holistic precision medicine. The study also provides strategic market forecasts, segment-level insights, and regional analysis to support informed business and investment decisions.

Market Dynamics

The rising global incidence of cancer remains one of the primary drivers of the market, creating substantial demand for faster, more accurate, and scalable diagnostic solutions as testing volumes continue to climb worldwide. The persistent global shortage of trained pathology professionals is further accelerating adoption, as computational tools help laboratories manage increasing workloads through automation, image analysis, and clinical decision support. Continuous advancements in artificial intelligence and deep learning are improving the ability of algorithms to identify complex tissue patterns with high consistency, while the expanding installed base of digital whole-slide imaging scanners is broadening the foundation available for computational analysis.

Despite this momentum, several challenges continue to influence adoption. The high capital investment required to implement a full computational pathology workflow, including high-speed scanners, high-performance computing infrastructure, and large-scale storage, remains a significant barrier for smaller laboratories. The complex and evolving regulatory landscape governing clinical AI algorithms can slow time-to-market for new products, and inconsistent image formats across scanner manufacturers, along with integration challenges with existing laboratory information systems, present ongoing technical hurdles.

The market nevertheless presents significant long-term opportunities. The integration of computational pathology with genomic and proteomic data is opening a path toward holistic, personalized precision medicine, while expansion into emerging markets with rapidly modernizing healthcare infrastructure presents substantial growth potential. The development of companion diagnostics that identify patients most likely to respond to targeted therapies offers strong potential for pharmaceutical partnerships, and the use of AI to predict treatment toxicity and long-term outcomes is emerging as a further avenue for growth.

Segment Analysis

The report provides detailed market analysis across product and service, deployment mode, application, end user, and geography, enabling stakeholders to identify high-growth business opportunities and evolving customer requirements.

Based on product and service, software holds the largest share of the market, encompassing whole-slide imaging software, AI-based image analysis tools, and case management systems that enable digital diagnostic workflows, with AI-based image analysis software representing the fastest-growing sub-segment as laboratories increasingly automate complex diagnostic tasks. From a deployment mode perspective, on-premise solutions currently account for the larger share given data control and security requirements at large academic medical centers, while cloud-based models are witnessing the fastest growth due to their scalability and lower upfront infrastructure costs.

Based on application, drug discovery and development accounts for the largest share as pharmaceutical companies were early adopters of computational pathology for biomarker discovery and quantifying treatment effects in clinical trials, while clinical diagnostics is projected to grow fastest as regulatory approvals expand the use of computational tools for routine cancer diagnosis in hospital settings.

Regional Analysis

The report provides comprehensive market analysis across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional evaluations consider research funding, pharmaceutical industry presence, digital health adoption, and pathology workforce dynamics influencing market growth.

North America currently accounts for the largest share of the global market, supported by robust research funding, a high concentration of leading pharmaceutical companies, and early adoption of digital health technologies. Europe continues to demonstrate steady growth, underpinned by strong academic pathology networks and increasing digital health investment across major markets.

Asia-Pacific is expected to register the fastest growth throughout the forecast period, supported by rapid modernization of diagnostic infrastructure and heavy investment in AI-driven healthcare solutions in countries including China and India. Latin America and the Middle East & Africa are also expected to offer emerging opportunities as healthcare digitalization and cancer care infrastructure continue to expand.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of key market participants, their scanner and software integration, AI algorithm capabilities, partnerships, acquisitions, geographic expansion initiatives, and recent business developments.

Competitive benchmarking enables stakeholders to evaluate companies based on clinical validity of AI models, interoperability with different scanner types, and strategic initiatives. The study also analyzes how market participants are strengthening their competitive position through strategic partnerships between scanner manufacturers and software developers to create seamless digital workflows, along with continued investment in cloud-native architectures to improve speed and scalability.

Key companies profiled in the report include Roche (Ventana Medical Systems), Danaher Corporation (Leica Biosystems), Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Nikon Corporation, Olympus Corporation (Evident), Hamamatsu Photonics K.K., Proscia Inc., Paige.AI, PathAI, Ibex Medical Analytics, Akoya Biosciences, Visiopharm A/S, and Indica Labs, among others.

How This Report Helps

Provides accurate market size estimates and long-term forecasts for the computational pathology market.

Evaluates the impact of AI-driven image analysis on diagnostic accuracy and laboratory throughput.

Identifies high-growth opportunities across products and services, deployment modes, applications, end users, and geographic regions.

Analyzes emerging technology trends, regulatory developments, and innovation pipelines.

Benchmarks leading companies based on scanner and software integration, strategic initiatives, and competitive positioning.

Supports product development, investment planning, partnership evaluation, market entry, and business expansion strategies.

Delivers actionable market intelligence for medical device manufacturers, hospitals, pharmaceutical companies, investors, and consultants.

Key Questions Answered

What is the current size of the global computational pathology market, and how is it expected to evolve through 2036?

Which clinical, technological, and demographic factors are driving market growth?

What are the major drivers, restraints, opportunities, and challenges influencing industry development?

Which product and service, deployment mode, application, end-user, and regional segments are expected to experience the strongest growth?

Which geographic markets present the most attractive business opportunities?

Who are the leading companies operating in the market, and what competitive strategies are they adopting?

What recent product launches, partnerships, acquisitions, and technological innovations are shaping the competitive landscape?

How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, and long-term business strategy?

TABLE OF CONTENTS

1. Market Definition & Scope

• 1.1. Market Definition
• 1.2. Market Ecosystem
• 1.3. Currency Considered
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
    • 2.3.1.1. Bottom-Up Approach
    • 2.3.1.2. Top-Down Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Assumptions for the Study

3. Executive Summary

• 3.1. Overview
• 3.2. Segmental Analysis
  • 3.2.1. Market Analysis, by Product & Service
  • 3.2.2. Market Analysis, by Deployment Mode
  • 3.2.3. Market Analysis, by Application
  • 3.2.4. Market Analysis, by End User
  • 3.2.5. Market Analysis, by Geography
• 3.3. Competitive Analysis

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Drivers
    • 4.2.1.1. Rising Incidence of Cancer and Increasing Diagnostic Workload
    • 4.2.1.2. Critical Shortage of Specialized Pathologists Globally
    • 4.2.1.3. Technological Advancements in AI and Deep Learning Models
  • 4.2.2. Restraints
    • 4.2.2.1. High Capital Investment for Scanners and Computing Infrastructure
    • 4.2.2.2. Complex and Evolving Regulatory Landscapes for Clinical AI
  • 4.2.3. Opportunities
    • 4.2.3.1. Integration with Multi-Omics Data for Holistic Precision Medicine
    • 4.2.3.2. Expansion into Rapidly Modernizing Emerging Markets in APAC and LATAM
  • 4.2.4. Challenges
    • 4.2.4.1. Lack of Standardized Image Formats Across Different Manufacturers
    • 4.2.4.2. Data Security and Privacy Concerns for Massive Patient Datasets
  • 4.2.5. Trends
    • 4.2.5.1. Shift Toward Cloud-Based SaaS Models for Scalability and Collaboration
    • 4.2.5.2. Increasing Regulatory Approvals for AI in Primary Clinical Diagnosis
• 4.3. Porter's Five Forces Analysis
• 4.4. Regulatory Landscape
• 4.5. Value Chain Analysis

5. Global Computational Pathology Market, by Product & Service

• 5.1. Overview
• 5.2. Software
  • 5.2.1. Whole Slide Imaging (WSI) Software
  • 5.2.2. AI-based Image Analysis Software
  • 5.2.3. Case Management Systems
• 5.3. Services
  • 5.3.1. Consulting & Implementation
  • 5.3.2. Training & Technical Support

6. Global Computational Pathology Market, by Deployment Mode

• 6.1. Overview
• 6.2. On-premise
• 6.3. Cloud-based (SaaS)

7. Global Computational Pathology Market, by Application

• 7.1. Overview
• 7.2. Drug Discovery & Development
• 7.3. Clinical Diagnostics
• 7.4. Education & Research

8. Global Computational Pathology Market, by End User

• 8.1. Overview
• 8.2. Hospitals & Diagnostic Labs
• 8.3. Pharmaceutical & Biotechnology Companies
• 8.4. Academic & Research Institutes

9. Global Computational Pathology Market, by Geography

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. U.K.
  • 9.3.3. France
  • 9.3.4. Netherlands
  • 9.3.5. Italy
  • 9.3.6. Rest of Europe
• 9.4. Asia-Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. South Korea
  • 9.4.5. Rest of Asia-Pacific
• 9.5. Latin America
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America
• 9.6. Middle East & Africa

10. Competitive Landscape

• 10.1. Overview
• 10.2. Key Growth Strategies
• 10.3. Competitive Dashboard
• 10.4. Vendor Market Positioning
• 10.5. Market Share Analysis, 2025

11. Company Profiles

• 11.1. Roche (Ventana Medical Systems)
• 11.2. Danaher Corporation (Leica Biosystems)
• 11.3. Siemens Healthineers AG
• 11.4. GE HealthCare Technologies Inc.
• 11.5. Philips Healthcare
• 11.6. Nikon Corporation
• 11.7. Olympus Corporation (Evident)
• 11.8. Hamamatsu Photonics K.K.
• 11.9. Proscia Inc.
• 11.10. Paige.AI
• 11.11. PathAI
• 11.12. Ibex Medical Analytics
• 11.13. Akoya Biosciences, Inc.
• 11.14. Visiopharm A/S
• 11.15. Indica Labs, Inc.

12. Appendix